On November 18, 2025, Zhifei Biologics (300122) held its second interim shareholders' meeting in Chongqing. With a high majority vote, it passed the relevant resolutions and legally abolished the board of supervisors.

The meeting passed the relevant proposals by a large majority, revised the "Company Charter", legally abolished the supervisory board, and transferred the relevant functions of the supervisory board to the audit committee of the board of directors. The director, Ms. Zhang Xinrong (former dean and professor of the Accounting College of Chongqing University of Commerce), took over these functions.

It is known that Zhifei Biological has made another breakthrough in its research and development recently.

The adjuvant cell-free diphtheria-tetanus-pertussis (component) combined vaccine (for adults and adolescents) (referred to as "diphtheria-tetanus-pertussis vaccine with components for adolescents and adults") developed by the wholly-owned subsidiary Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. has received the drug clinical trial approval notice from the National Medical Products Administration, allowing for the conduct of clinical trials to prevent infectious diseases caused by diphtheria, tetanus and pertussis.

This vaccine is a new generation of cell-free diphtheria-tetanus-pertussis vaccine. It is a uniformly quality vaccine product formulated by separately purifying the effective components of pertussis, combined with the effective components of diphtheria and tetanus. It is suitable for healthy individuals aged 7 and above for the prevention of pertussis, diphtheria and tetanus.

As of now, there are no component DPT vaccines suitable for both teenagers and adults that have been approved for market release in China, and the market prospects are very promising.

In addition, among the research pipeline of Zhifei Biological, the adjuvantless cell-free diphtheria-tetanus-pertussis (component) combined vaccine is undergoing Phase III clinical trials, and the component diphtheria-tetanus-Hib quadruple vaccine has received the clinical trial approval notice.

On the evening of November 19th, ZhiFei Biologics disclosed that the recombinant herpes zoster ZFA01 adjuvant vaccine (CHO cells), developed by its wholly-owned subsidiary ANHUI ZHIFEI LONGCOM BIOPHARMACEUTICAL CO.,LTD., has received the drug clinical trial application acceptance notice from the National Medical Products Administration.

On November 18th, Chongqing Genrix Biopharmaceutical Co., Ltd.(688443) also held its first interim general meeting of shareholders in 2025 at the Junhao Grand Hotel in Chongqing. With a high vote, it passed the relevant resolutions, revised the "Company Charter", legally abolished the board of supervisors, and the relevant functions of the board of supervisors were taken over by the audit committee of the board of directors. The chairperson, Hu Yuntong (professor at Southwest University of Political Science and Law, lawyer, non-practicing member of the Chinese Institute of Certified Public Accountants), was appointed in this capacity.

It is reported that in the third quarter, Genrix Bio. has made significant progress on several ongoing research projects.

In July, the clinical trial application for the passive immunization indication of silewarmimab injection for suspected rabies virus exposure in children and adolescents aged 2 to 18 years was approved by the National Medical Products Administration, and the III-phase clinical trial was initiated; in August, the clinical trial applications for the adult seasonal allergic rhinitis indication and the adolescent seasonal allergic rhinitis indication of talichibai single antibody injection (GR1802) were successively approved by the National Medical Products Administration and the III-phase clinical trial was initiated; in September, the clinical trial applications for the inflammatory bowel disease indication of GR2303 injection, the systemic lupus erythematosus indication of GR1803 injection, and the vitiligo indication of GR2301 injection were successively approved by the National Medical Products Administration, and the new drug marketing application for the adult moderate-to-severe atopic dermatitis indication of talichibai single antibody injection (GR1802) was accepted by the National Medical Products Administration.

https://finance.eastmoney.com/a/202511193569110145.html